Popular on Rezul
- Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 181
- JiT Home Buyers Expands Local Presence to 18 Real Estate Markets Across the United States - 155
- Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention - 143
- Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety - 134
- The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma - 132
- Sales Blueprint Architect Launches, Helping Sales Professionals, Business Owners, and Consultants Close More Business With AI - 112
- CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards - 104
- New Book, The KI of Marketing, Helps Small Businesses Grow Without Trying to Outspend Bigger Competitors
- PulteGroup expands Northeast Florida presence with Oakmere coming soon to Mandarin
- DuoKey launches the World's First Agentic Crypto Agility Platform
Similar on Rezul
- International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
- Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
- European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- Mandeville Pests May Pose Serious Health Risks for Your Family
- Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
- Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
- Amaris Mint® Confirms UK Availability of Swedish-Made BioBoost Daily Nutrition Range
Direct Biologics to Support ARDS Alliance as Educational Sponsor
Rezul News/10745671
Educational program will provide science-based information on extracellular vesicle science, secretome research and investigational biologic approaches in ARDS
AUSTIN, Texas - Rezul -- Direct Biologics, LLC will serve as an Educational Sponsor of an upcoming educational webinar produced by ARDS Alliance, Inc. focused on Acute Respiratory Distress Syndrome, Extracellular Vesicle science, secretome research and investigational biologic approaches.
Supported through an educational grant from Direct Biologics, the webinar is being independently developed and produced by ARDS Alliance. The program is intended to provide patients, caregivers and other members of the ARDS community with accurate, science-based educational information and to help address common misconceptions surrounding investigational approaches, including their regulatory status.
The educational program will feature an independent physician or researcher as well as a patient perspective highlighting the experience and impact of ARDS. ARDS Alliance will independently select the speakers and maintain sole editorial control over the webinar and its educational content.
More on Rezul News
"The importance of independent, science-based education for patients and families, and our appreciation for the educational support that makes these programs possible, cannot be overstated," said Paula Blonski, President of ARDS Alliance.
"ARDS is a complex and serious condition, and access to credible, understandable scientific information is important for patients and families navigating it," said Tim Moseley PhD, CSO of Direct Biologics. "We are pleased to support ARDS Alliance in its efforts to provide independent education to the ARDS community."
Direct Biologics' sponsorship is limited to financial support of the educational program and does not provide the company with editorial control over the webinar. Sponsorship does not constitute an endorsement by ARDS Alliance of Direct Biologics, its products or any specific therapy.
The webinar is expected to take place later this year with the recording available through ARDS Alliance and Direct Biologics.
The ARDS Alliance is dedicated to improving ARDS outcomes. By collaborating with patient advocates, healthcare experts, and scientific researchers, the ARDS Alliance works to accelerate research, improve clinical recognition, and advance the global standard of care for respiratory failure.
More on Rezul News
Direct Biologics (https://www.directbiologics.com/) develops investigational secretome-based products under cGMP standards, guided by scientific rigor. All candidate therapies are investigational and have not been approved by the U.S. Food and Drug Administration.
Important Notice
The ARDS Alliance webinar is an independent educational program produced and controlled solely by ARDS Alliance. Direct Biologics' sponsorship does not constitute endorsement by ARDS Alliance of Direct Biologics, its products or any specific therapy. Any investigational therapies discussed during the educational program are under investigation and have not been approved by the U.S. Food and Drug Administration for the indications discussed, unless expressly identified otherwise. The webinar is intended solely for educational purposes and is not intended to provide medical advice, establish a standard of care or recommend the use of any investigational or approved product.
Supported through an educational grant from Direct Biologics, the webinar is being independently developed and produced by ARDS Alliance. The program is intended to provide patients, caregivers and other members of the ARDS community with accurate, science-based educational information and to help address common misconceptions surrounding investigational approaches, including their regulatory status.
The educational program will feature an independent physician or researcher as well as a patient perspective highlighting the experience and impact of ARDS. ARDS Alliance will independently select the speakers and maintain sole editorial control over the webinar and its educational content.
More on Rezul News
- Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
- Phoenix REALTOR® Jennifer Alvarez Expands Resources for Attorneys and Clients Navigating Complex Real Estate Matters
- Fairhope Home Prices Hold Steady Through August 2026 as Sales Pace Slows
- Stockdale Capital Partners Launches Real Estate Credit Platform
- Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
"The importance of independent, science-based education for patients and families, and our appreciation for the educational support that makes these programs possible, cannot be overstated," said Paula Blonski, President of ARDS Alliance.
"ARDS is a complex and serious condition, and access to credible, understandable scientific information is important for patients and families navigating it," said Tim Moseley PhD, CSO of Direct Biologics. "We are pleased to support ARDS Alliance in its efforts to provide independent education to the ARDS community."
Direct Biologics' sponsorship is limited to financial support of the educational program and does not provide the company with editorial control over the webinar. Sponsorship does not constitute an endorsement by ARDS Alliance of Direct Biologics, its products or any specific therapy.
The webinar is expected to take place later this year with the recording available through ARDS Alliance and Direct Biologics.
The ARDS Alliance is dedicated to improving ARDS outcomes. By collaborating with patient advocates, healthcare experts, and scientific researchers, the ARDS Alliance works to accelerate research, improve clinical recognition, and advance the global standard of care for respiratory failure.
More on Rezul News
- FOCUS Names Mark Phillips Senior Vice President of Business Development
- Notaron Expands Online Notarization Access Following Wisconsin Approval
- Wings Air Helicopters Selected to Support VIP Transportation for Resorts World in New York
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
- Gaby Diaz Helps Spanish-Speaking Buyers Navigate Miami's Housing Market
Direct Biologics (https://www.directbiologics.com/) develops investigational secretome-based products under cGMP standards, guided by scientific rigor. All candidate therapies are investigational and have not been approved by the U.S. Food and Drug Administration.
Important Notice
The ARDS Alliance webinar is an independent educational program produced and controlled solely by ARDS Alliance. Direct Biologics' sponsorship does not constitute endorsement by ARDS Alliance of Direct Biologics, its products or any specific therapy. Any investigational therapies discussed during the educational program are under investigation and have not been approved by the U.S. Food and Drug Administration for the indications discussed, unless expressly identified otherwise. The webinar is intended solely for educational purposes and is not intended to provide medical advice, establish a standard of care or recommend the use of any investigational or approved product.
Source: ARDS Alliance
0 Comments
Latest on Rezul News
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
- Downtown Sarasota Luxury Condo Sales Rise 39.8% Through August 2026 as Marketing Time Lengthens
- BIC Homes Offers Affordable Luxury New Homes in Northeast El Paso, TX
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- Indian Shores STR Condo Sales Rise 50% Year to Date as Median Price Falls 7% in 2026
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
- Land For Sale Lake Conroe TX – Lots & Acreage
- Shelter Structures America makes European debut at TEMPOR EXPO 2026 in Fulda, Germany
- HydroExcavation.com Relaunches With Exclusive Local Service Areas and Dedicated Hydrovac Manufacturer Directory
- ClearLead Digital Launches New Website for Smart Move Property Management
- David Weekley Homes Debuts Three New Floor Plans in Forsyth County
- Sky Quarry Enters a Powerful New Chapter: Refinery Restart Emminent, Nevada Oil Initiative and Visibility Put (NAS DAQ: SKYQ) in the Spotlight
- OneVizion Launches Vera AI, Bringing Connected Operational Context to Infrastructure Teams
- P-Wave Press Announces Pushing the Wave 2025 by L.A. Davenport
- DONGSHENG Titanium Recycling: Promoting a Closed-Loop Cycle for High-End Titanium Materials
- Rural California Energy Consultancy Unlocks Remote Sites for Vacation Rentals and ADUs
- Apple Valley Home Sales Rise 22.0% as Active Listings Fall 20.2%
- French Camp Academy Releases New Video Inviting Individuals to Consider a Life of Service
- LET US READ Documentary on Dyslexia and Literacy to Screen at TCL Chinese 6 in Hollywood